COVID-19 in transplant recipients : The Spanish experience
© 2020 The American Society of Transplantation and the American Society of Transplant Surgeons..
We report the nationwide experience with solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients diagnosed with coronavirus disease 2019 (COVID-19) in Spain until 13 July 2020. We compiled information for 778 (423 kidney, 113 HSCT, 110 liver, 69 heart, 54 lung, 8 pancreas, 1 multivisceral) recipients. Median age at diagnosis was 61 years (interquartile range [IQR]: 52-70), and 66% were male. The incidence of COVID-19 in SOT recipients was two-fold higher compared to the Spanish general population. The median interval from transplantation was 59 months (IQR: 18-131). Infection was hospital-acquired in 13% of cases. No donor-derived COVID-19 was suspected. Most patients (89%) were admitted to the hospital. Therapies included hydroxychloroquine (84%), azithromycin (53%), protease inhibitors (37%), and interferon-β (5%), whereas immunomodulation was based on corticosteroids (41%) and tocilizumab (21%). Adjustment of immunosuppression was performed in 85% of patients. At the time of analysis, complete follow-up was available from 652 patients. Acute respiratory distress syndrome occurred in 35% of patients. Ultimately, 174 (27%) patients died. In univariate analysis, risk factors for death were lung transplantation (odds ratio [OR]: 2.5; 95% CI: 1.4-4.6), age >60 years (OR: 3.7; 95% CI: 2.5-5.5), and hospital-acquired COVID-19 (OR: 3.0; 95% CI: 1.9-4.9).
| Errataetall: |
CommentIn: Am J Transplant. 2021 Jun;21(6):2311-2313. - PMID 33450112 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons - 21(2021), 5 vom: 05. Mai, Seite 1825-1837 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Antibiotic: antiviral |
|---|
| Anmerkungen: |
Date Completed 13.05.2021 Date Revised 03.11.2023 published: Print-Electronic CommentIn: Am J Transplant. 2021 Jun;21(6):2311-2313. - PMID 33450112 Citation Status MEDLINE |
|---|
| doi: |
10.1111/ajt.16369 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316670375 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316670375 | ||
| 003 | DE-627 | ||
| 005 | 20231225161606.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/ajt.16369 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1055.xml |
| 035 | |a (DE-627)NLM316670375 | ||
| 035 | |a (NLM)33098200 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Coll, Elisabeth |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 in transplant recipients |b The Spanish experience |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.05.2021 | ||
| 500 | |a Date Revised 03.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Am J Transplant. 2021 Jun;21(6):2311-2313. - PMID 33450112 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 The American Society of Transplantation and the American Society of Transplant Surgeons. | ||
| 520 | |a We report the nationwide experience with solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients diagnosed with coronavirus disease 2019 (COVID-19) in Spain until 13 July 2020. We compiled information for 778 (423 kidney, 113 HSCT, 110 liver, 69 heart, 54 lung, 8 pancreas, 1 multivisceral) recipients. Median age at diagnosis was 61 years (interquartile range [IQR]: 52-70), and 66% were male. The incidence of COVID-19 in SOT recipients was two-fold higher compared to the Spanish general population. The median interval from transplantation was 59 months (IQR: 18-131). Infection was hospital-acquired in 13% of cases. No donor-derived COVID-19 was suspected. Most patients (89%) were admitted to the hospital. Therapies included hydroxychloroquine (84%), azithromycin (53%), protease inhibitors (37%), and interferon-β (5%), whereas immunomodulation was based on corticosteroids (41%) and tocilizumab (21%). Adjustment of immunosuppression was performed in 85% of patients. At the time of analysis, complete follow-up was available from 652 patients. Acute respiratory distress syndrome occurred in 35% of patients. Ultimately, 174 (27%) patients died. In univariate analysis, risk factors for death were lung transplantation (odds ratio [OR]: 2.5; 95% CI: 1.4-4.6), age >60 years (OR: 3.7; 95% CI: 2.5-5.5), and hospital-acquired COVID-19 (OR: 3.0; 95% CI: 1.9-4.9) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a antibiotic: antiviral | |
| 650 | 4 | |a clinical decision-making | |
| 650 | 4 | |a clinical research/practice | |
| 650 | 4 | |a complication: infectious | |
| 650 | 4 | |a infection and infectious agents - viral | |
| 650 | 4 | |a infectious disease | |
| 700 | 1 | |a Fernández-Ruiz, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez-Álvarez, J Emilio |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-Fernández, José R |e verfasserin |4 aut | |
| 700 | 1 | |a Crespo, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Gayoso, Jorge |e verfasserin |4 aut | |
| 700 | 1 | |a Bada-Bosch, Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Oppenheimer, Federico |e verfasserin |4 aut | |
| 700 | 1 | |a Moreso, Francesc |e verfasserin |4 aut | |
| 700 | 1 | |a López-Oliva, María O |e verfasserin |4 aut | |
| 700 | 1 | |a Melilli, Edoardo |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Ferrero, Marisa L |e verfasserin |4 aut | |
| 700 | 1 | |a Bravo, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Burgos, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Facundo, Carme |e verfasserin |4 aut | |
| 700 | 1 | |a Lorenzo, Inmaculada |e verfasserin |4 aut | |
| 700 | 1 | |a Yañez, Íñigo |e verfasserin |4 aut | |
| 700 | 1 | |a Galeano, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Roca, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Cabello, Mercedes |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez-Bueno, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a García-Cosío, MªDolores |e verfasserin |4 aut | |
| 700 | 1 | |a Graus, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Lladó, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a de Pablo, Alicia |e verfasserin |4 aut | |
| 700 | 1 | |a Loinaz, Carmelo |e verfasserin |4 aut | |
| 700 | 1 | |a Aguado, Beatriz |e verfasserin |4 aut | |
| 700 | 1 | |a Hernández, Domingo |e verfasserin |4 aut | |
| 700 | 1 | |a Domínguez-Gil, Beatriz |e verfasserin |4 aut | |
| 700 | 0 | |a Spanish Group for the Study of COVID-19 in Transplant Recipients |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons |d 2001 |g 21(2021), 5 vom: 05. Mai, Seite 1825-1837 |w (DE-627)NLM119667924 |x 1600-6143 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2021 |g number:5 |g day:05 |g month:05 |g pages:1825-1837 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/ajt.16369 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2021 |e 5 |b 05 |c 05 |h 1825-1837 | ||